| (84) |
Benannte Vertragsstaaten: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (43) |
Veröffentlichungstag der Anmeldung: |
|
24.07.2019 Patentblatt 2019/30 |
| (73) |
Patentinhaber: Sterna Biologicals GmbH |
|
35039 Marburg (DE) |
|
| (72) |
Erfinder: |
|
- Renz, Jonas
81675 München (DE)
|
| (74) |
Vertreter: Pharma Patents International AG |
|
Leonhardsgraben 52
Postfach
4001 Basel
4001 Basel (CH) |
| (56) |
Entgegenhaltungen: :
WO-A1-2017/205506
WO-A2-2014/040891
|
WO-A2-2005/033314
US-A1- 2003 040 497
|
|
| |
|
|
- POPP VANESSA ET AL: "Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription
Factor GATA3 and Reduces Colitis in Mice", GASTROENTEROLOGY, W.B. SAUNDERS CO, US,
Bd. 152, Nr. 1, 14. September 2016 (2016-09-14), Seiten 176-192, XP029851140, ISSN:
0016-5085, DOI: 10.1053/J.GASTRO.2016.09.005
- Anonymous: "DRKS-ID: DRKS00007193 SB012 for the Treatment of Active Ulcerative Colitis
(SECURE): a Prospective, Single-centre, Randomised, Double-blind, Placebo-controlled
Phase IIa Clinical Trial to Evaluate the Efficacy, Pharmacokinetics, Tolerability,
and Safety of SB012 Enema Administered Once Daily", , 9. Juni 2015 (2015-06-09), XP055476967,
Gefunden im Internet: URL:http://www.drks.de/drks_web/navigate.d o?navigationId=trial.HTML&TRIAL_ID=DRKS000
07193 [gefunden am 2018-05-18]
- WEIGMANN BENNO ET AL: "Suppression of Experimental Ulcerative Colitis by Topical Delivery
of Specific Dnazyme Blocking Thetranscription Factor GATA3", GASTROENTEROLOGY, W.B.
SAUNDERS CO, US, 22. April 2017 (2017-04-22), XP085104521, ISSN: 0016-5085, DOI: 10.1016/S0016-5085(17)32631-8
- KATRINA RAY: "A role for GATA3 in ulcerative colitis", NATURE REVIEWS / GASTROENTEROLOGY
& HEPATOLOGY, Bd. 13, Nr. 11, 5. Oktober 2016 (2016-10-05), Seiten 624-624, XP55476486,
US ISSN: 1759-5045, DOI: 10.1038/nrgastro.2016.163
- ALESYA A. FOKINA ET AL: "Delivery of therapeutic RNA-cleaving oligodeoxyribonucleotides
(deoxyribozymes): from cell culture studies to clinical trials", EXPERT OPINION ON
DRUG DELIVERY, Bd. 14, Nr. 9, 7. Dezember 2016 (2016-12-07), Seiten 1077-1089, XP55476495,
GB ISSN: 1742-5247, DOI: 10.1080/17425247.2017.1266326
- URBANSKA ALEKSANDRA M ET AL: "What's Next for Gastrointestinal Disorders: No Needles?",
JOURNAL OF CONTROLLED RELEASE, Bd. 221, 2. Dezember 2015 (2015-12-02), Seiten 48-61,
XP029383249, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2015.11.031
- Zhijie Xu ET AL: "Small-molecule Nucleic-acid-based Gene-silencing Strategies" In:
"Nucleic Acids - From Basic Aspects to Laboratory Tools", 16. März 2016 (2016-03-16),
InTech, XP55476951, ISBN: 978-953-51-2264-7 DOI: 10.5772/62137, * Tabelle 2 *
- HOLGER GARN ET AL: "GATA-3-specific DNAzyme - A novel approach for stratified asthma
therapy", EUROPEAN JOURNAL OF IMMUNOLOGY, Bd. 47, Nr. 1, 2. Dezember 2016 (2016-12-02),
Seiten 22-30, XP055476945, ISSN: 0014-2980, DOI: 10.1002/eji.201646450
- COMINELLI FABIO ET AL: "Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease
Using Mouse Models of Crohn's Disease-Like Ileitis: What is the Right Model?", CELLULAR
AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY JUL 2017, vol. 4, no. 1, July 2017 (2017-07),
pages 19-32, ISSN: 2352-345X
- KOELINK PJ AND TE VELDE AA: "Mistakes in mouse models of IBD and how to avoid them.",
UEG EDUCATION, vol. 16, 2016, pages 11-14,
- NGUYEN THI LOAN ANH ET AL: "How informative is the mouse for human gut microbiota
research?", DISEASE MODELS & MECHANISMS JAN 2015, vol. 8, no. 1, January 2015 (2015-01),
pages 1-16, ISSN: 1754-8411
- ALDARS-GARCÍA LAILA ET AL: "The Interplay between Immune System and Microbiota in
Inflammatory Bowel Disease: A Narrative Review.", INTERNATIONAL JOURNAL OF MOLECULAR
SCIENCES 17 MAR 2021, vol. 22, no. 6, 17 March 2021 (2021-03-17) , ISSN: 1422-0067
- CROUWEL FEMKE ET AL: "Gut microbiota-driven drug metabolism in inflammatory bowel
disease.", JOURNAL OF CROHN'S & COLITIS 11 JUL 2020, 11 July 2020 (2020-07-11), ISSN:
1876-4479
- VALATAS VASSILIS ET AL: "The value of experimental models of colitis in predicting
efficacy of biological therapies for inflammatory bowel diseases.", AMERICAN JOURNAL
OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY DEC 2013, vol. 305, no. 11, December
2013 (2013-12), pages G763-G785, ISSN: 1522-1547
- VICTOR JULIAN ET AL: "Inability of DNAzymes to cleave RNA in vivo is due to limited
Mg[Formula: see text] concentration in cells.", EUROPEAN BIOPHYSICS JOURNAL : EBJ
MAY 2018, vol. 47, no. 4, May 2018 (2018-05), pages 333-343, ISSN: 1432-1017
- TRAPANI VALENTINA ET AL: "Dietary Magnesium Alleviates Experimental Murine Colitis
Through Upregulation of the Transient Receptor Potential Melastatin 6 Channel.", INFLAMMATORY
BOWEL DISEASES 15 09 2018, vol. 24, no. 10, 15 September 2018 (2018-09-15), pages
2198-2210, ISSN: 1536-4844
- SWANSON KENNETH D ET AL: "Reproducing the human mucosal environment ex vivo: inflammatory
bowel disease as a paradigm.", CURRENT OPINION IN GASTROENTEROLOGY 11 2018, vol. 34,
no. 6, November 2018 (2018-11), pages 384-391, ISSN: 1531-7056
|
|
